Protocol Ledger

NCT04628767 · Phase II/III · RECRUITING

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Interventional Phase II/III clinical trial protocol NCT04628767 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-12 Enrollment: 131 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04628767
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)131 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04628767
Protocol FieldVerified Registry Value
NCT IdentifierNCT04628767
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment131 participants (ESTIMATED)
Registered Start Date2021-11-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI